Valuation Metrics Reflect Improved Price Attractiveness
Epigral’s current price-to-earnings (P/E) ratio stands at 17.28, a significant discount compared to its specialty chemicals peers, many of whom trade at P/E multiples exceeding 30. For instance, Navin Fluorine International and Himadri Speciality Chemicals are valued at P/E ratios of 53.99 and 42.62 respectively, underscoring Epigral’s relative affordability. The company’s price-to-book value (P/BV) is 2.58, which, while not low in absolute terms, remains modest compared to sector heavyweights.
Enterprise value to EBITDA (EV/EBITDA) ratio of 11.12 further supports the attractive valuation narrative. This contrasts sharply with peers such as Acutaas Chemicals and Sumitomo Chemical, whose EV/EBITDA multiples exceed 35, signalling stretched valuations in the broader sector. Epigral’s EV to EBIT ratio of 15.81 and EV to capital employed of 2.26 also indicate a more reasonable pricing relative to earnings and capital base.
Financial Performance and Returns
Epigral’s return on capital employed (ROCE) and return on equity (ROE) stand at 14.30% and 14.94% respectively, reflecting solid operational efficiency and shareholder returns. These figures are respectable within the specialty chemicals industry, where capital intensity and margin pressures often challenge profitability. The company’s PEG ratio is reported as 0.00, which may indicate either a lack of earnings growth projection or data unavailability, but the low P/E relative to growth prospects suggests undervaluation.
Despite a recent day change of -3.22%, Epigral’s stock has outperformed the Sensex over multiple time horizons. The stock delivered a 10.33% return over the past week and an impressive 31.3% gain over the last month, while the Sensex remained largely flat or negative in these periods. Year-to-date, Epigral has returned 8.88%, outperforming the Sensex’s -9.26%. However, over the last year, the stock declined by 24.78%, underperforming the benchmark’s -3.74%, reflecting some volatility and sector-specific headwinds.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Comparative Valuation: Epigral vs Peers
When benchmarked against its peers in the specialty chemicals sector, Epigral’s valuation stands out as notably attractive. Most competitors are classified as very expensive or expensive, with P/E ratios ranging from approximately 30 to over 70. For example, Aether Industries trades at a P/E of 72.66 and an EV/EBITDA of 45.72, while Vinati Organics commands a P/E of 32.77 and EV/EBITDA of 21.66. In contrast, Epigral’s P/E of 17.28 and EV/EBITDA of 11.12 suggest a significant valuation discount.
This valuation gap may reflect market concerns over Epigral’s smaller market capitalisation and recent share price volatility, but it also presents a potential entry point for investors seeking exposure to the specialty chemicals sector at a more reasonable price. The company’s mojo score of 34.0 and a recent upgrade from a strong sell to a sell rating on 26 Dec 2025 indicate a cautious but improving outlook.
Price Movement and Market Context
Epigral’s current share price is ₹1,327.55, down from a previous close of ₹1,371.75, with intraday trading ranging between ₹1,325.05 and ₹1,383.00. The stock’s 52-week high is ₹2,114.30, while the low is ₹806.20, illustrating a wide trading range and significant volatility over the past year. This volatility is partly attributable to broader market fluctuations and sector-specific dynamics, including raw material cost pressures and regulatory developments.
Despite the recent downward pressure, the stock’s longer-term performance remains robust, with a three-year return of 38.61% compared to the Sensex’s 25.20%. This outperformance highlights Epigral’s resilience and growth potential relative to the broader market.
Holding Epigral Ltd from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investment Implications and Outlook
The shift in Epigral’s valuation grade from fair to attractive signals a potential inflection point for investors seeking value in the specialty chemicals sector. The company’s relatively low P/E and EV/EBITDA multiples, combined with solid returns on capital and equity, suggest that the market may be underestimating its growth prospects and operational efficiency.
However, investors should remain mindful of the stock’s recent price volatility and the sector’s overall expensive valuation environment. While Epigral’s mojo grade has improved from strong sell to sell, indicating some positive momentum, the small-cap status and competitive pressures warrant a cautious approach.
For those considering exposure to specialty chemicals, Epigral offers a differentiated valuation profile that contrasts with the high multiples seen in larger peers. This could provide a margin of safety and upside potential if the company continues to deliver on operational metrics and market conditions stabilise.
Conclusion
Epigral Ltd’s recent valuation adjustment to an attractive rating, supported by a P/E of 17.28 and EV/EBITDA of 11.12, positions it as a compelling candidate for investors seeking value in the specialty chemicals sector. Despite a challenging year marked by share price declines and sector-wide expensive valuations, the company’s solid returns and improving mojo grade suggest potential for recovery and growth. Careful monitoring of market dynamics and peer performance will be essential for investors aiming to capitalise on this valuation shift.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
